Antonio Tursi

44PUBLICATIONS
100CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological modellingRheumatology and arthritisMedical bacteriologyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Jun 18, 2026
An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patients.

|May 05, 2026
The DICA endoscopic score and the CODA clinical score may predict the severity of acute diverticulitis and the risk of hospitalisation: results from an international multicentre prospective cohort study.

|Mar 24, 2026
Analysis of possible baseline and treatment-course factors associated with non-remission in patients with Crohn's disease treated with ustekinumab: a retrospective real-life analysis.

Antonio Tursi, Raffaele Pellegrino, Giammarco Mocci

|Mar 18, 2026
Optimal use of rifaximin in diverticular disease of the colon: use less for use better.

Antonio Tursi

|Mar 05, 2026
Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis.

Antonio Tursi, Andrea Pasta, Walter Elisei

|Feb 18, 2026
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.

Franco Scaldaferri, Federica Di Vincenzo, Marina Aloi

Pageof 8

Frequent Collaborators

10 joint publications

Alfredo Papa

9 joint publications

Edoardo Vincenzo Savarino

8 joint publications

Giammarco Mocci

7 joint publications

Antonietta Gerarda Gravina